Skip to main content

Erdanib 4 mg & 5 mg (Erdafitinib)

Erdanib is identified on this website as an erdafitinib-containing product in stated 4 mg and 5 mg strengths.

Product identity

CharacteristicInformation
ProductErdanib
Active ingredientErdafitinib
Stated strengths4 mg and 5 mg
Drug classFGFR tyrosine kinase inhibitor
Therapeutic categoryAntineoplastic
Reference productBALVERSA
Original discovery/developmentAstex Pharmaceuticals and Janssen
Erdanib manufacturerDrug International Limited

Therapeutic role

Erdafitinib is used in selected patients with advanced urothelial carcinoma carrying susceptible FGFR3 alterations. Current U.S. labeling requires molecular selection using an FDA-approved companion diagnostic.

Reference product

BALVERSA is the established branded erdafitinib product in the U.S. and EU regulatory sources reviewed.

Development history

Erdafitinib was discovered through Astex’s FGFR research program in collaboration with Janssen. Astex reports that the collaboration began in 2008 and that Janssen was responsible for clinical development and commercialization.

Safety

Important safety considerations include ocular toxicity, hyperphosphatemia, stomatitis, nail disorders, palmar-plantar erythrodysesthesia and other adverse effects.

Product verification

The actual Erdanib package should be checked against reliable manufacturer and regulatory documentation before use.